Biogen (BIIB) -0.8% following its Q1 miss, which was due to weaker-than-expected sales of its...

|About: Biogen Inc. (BIIB)|By:, SA News Editor

Biogen (BIIB) -0.8% following its Q1 miss, which was due to weaker-than-expected sales of its Avonex multiple sclerosis drug. Still, net profit edged up 3% to $302.7M. Biogen upgraded its 2012 outlook, and it now expects adjusted EPS of over $6.15 and revenue growth in the mid-single digits.